Egcg, a dyrk1a Inhibitor as Therapeutic Tool for Reversing Cognitive Deficits in Down Syndrome Individuals.
NCT01394796
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
31
Enrollment
OTHER
Sponsor class
Conditions
Down Syndrome
Interventions
DIETARY_SUPPLEMENT:
Epigallocatechin-3-gallate (EGCG)
DRUG:
Placebo
Sponsor
Parc de Salut Mar